Intraperitoneal CF33-hNIS combined with PD-L1 blockade eradicates gastric cancer peritoneal metastases and prevents recurrence via durable T cell memory
Journal for ImmunoTherapy of Cancer · 2026
DOI: 10.1136/jitc-2025-014530 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2026. Verfasst von Annie Yang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Depratment of Surgery, City of Hope National Medical Center, Duarte, California, USA. Hauptthemen laut MEDLINE: Stomach Neoplasms, Peritoneal Neoplasms, Immune Checkpoint Inhibitors, B7-H1 Antigen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Department of Surgery Start-Up Grant City of Hope.
Abstract (Originalsprache)
Background
Peritoneal metastasis (PM) from gastric cancer (GC) is associated with poor prognosis and limited treatment options. We investigated a novel peritoneal-targeted therapy using CF33-human sodium iodide symporter (hNIS), a chimeric orthopoxvirus, combined with anti-PD-L1 immune checkpoint blockade in an immunocompetent mouse model of GCPM.
Methods
We evaluated replication and cytotoxicity of CF33-hNIS in human and murine GC cell lines. We assessed a syngeneic mouse model of PM using the transgenic mouse GC ACKPY3944 cells to test the efficacy of intraperitoneal (IP) CF33-hNIS alone and combined with intravenous or IP anti-PD-L1. Next, we performed flow cytometry and immunohistochemistry to analyze immune cell populations of CD3 + T cell subsets in the peritoneal cavity and tumor microenvironment. Mice that showed complete tumor regression (CTR) were rechallenged with ACKPY3944 cells to assess memory T cell responses.
Results
CF33-hNIS efficiently infected and killed GC cells. In vivo, IP CF33-hNIS alone significantly prolonged survival and increased infiltration of CD3 + and CD8 + T cells within the peritoneal cavity and solid tumor. The most pronounced therapeutic effect was observed with a single high-dose of CF33-hNIS (10 8 plaque-forming units) combined with IP anti-PD-L1 (Combo 2) with 75% CTR. Notably, mice with CTR rejected tumor rechallenge, exhibiting significantly elevated effector and central memory T cell populations in the peritoneal cavity and spleen. IP CF33-hNIS demonstrates robust anti-tumor efficacy against GCPM, particularly when combined with IP anti-PD-L1 in the high-dose Combo 2 regimen.
Conclusions
These findings support a simplified, high-dose IP treatment strategy to overcome immune resistance in GCPM and provide a strong rationale for future clinical evaluation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Depratment of Surgery, City of Hope National Medical Center, Duarte, California, USA.
- Depratment of Surgery, City of Hope National Medical Center, Duarte, California, USA yhwoo@coh.org zhifangzhang04@yahoo.com.
- Cancer Immunotherapeutics Program, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA.
Förderung
- Department of Surgery Start-Up Grant City of Hope
Zitieren
APA
Yang, A., Zhang, Z., Park, A. K., Chaurasiya, S., Kim, S. I., Lu, J., Vashi, Y., Cillis, J., Valencia, H., Chen, C., Deshpande, S., Fong, Y., & Woo, Y. (2026). Intraperitoneal CF33-hNIS combined with PD-L1 blockade eradicates gastric cancer peritoneal metastases and prevents recurrence via durable T cell memory. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-014530
Vancouver
Yang A, Zhang Z, Park AK, Chaurasiya S, Kim SI, Lu J, et al. Intraperitoneal CF33-hNIS combined with PD-L1 blockade eradicates gastric cancer peritoneal metastases and prevents recurrence via durable T cell memory. Journal for ImmunoTherapy of Cancer. 2026. doi:10.1136/jitc-2025-014530
BibTeX
@article{Yang2026,
author = {Yang, Annie and Zhang, Zhifang and Park, Anthony K and Chaurasiya, Shyambabu and Kim, Sang-In and Lu, Jianming and Vashi, Yoya and Cillis, Jennifer and Valencia, Hannah and Chen, Courtney and Deshpande, Supriya and Fong, Yuman and Woo, Yanghee},
title = {Intraperitoneal CF33-hNIS combined with PD-L1 blockade eradicates gastric cancer peritoneal metastases and prevents recurrence via durable T cell memory},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
doi = {10.1136/jitc-2025-014530}
}
EUVIMED